The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy - PubMed (original) (raw)
Meta-Analysis
doi: 10.1038/ki.2011.413. Epub 2011 Dec 21.
Affiliations
- PMID: 22189841
- DOI: 10.1038/ki.2011.413
Free article
Meta-Analysis
The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy
Jennifer A Hirst et al. Kidney Int. 2012 Apr.
Free article
Abstract
Renin-angiotensin-aldosterone system inhibitors prevent the progression of kidney disease in patients with diabetic nephropathy, and we studied how that benefit varies by the type of diabetes and baseline urinary albumin. We pooled data from 49 randomized controlled trials in a meta-analysis using the ratio of endpoint urinary albumin levels in those treated compared to those untreated with renin-angiotensin-aldosterone system inhibitors in both fixed- and random-effects models. The urinary albumin excretion for treated microalbuminuric patients with Type 1 diabetes was on average 60% lower at the end of the trial compared with patients not treated with renin-angiotensin-aldosterone system inhibitors using the fixed-effects model and 67% lower using the random-effects model. There was no significant effect of treatment in patients with normal albumin excretion. For normoalbuminuric patients with Type 2 diabetes, urinary albumin excretion was on average 12% lower after treatment using the fixed-effects model compared to 21% lower using the random-effects model. For microalbuminuric patients, urinary albumin excretion was on average 23% lower using the fixed-effects model and 27% lower using the random-effects model. Thus, renin-angiotensin-aldosterone system inhibition reduced urinary albumin excretion for Type 1 diabetic patients with micro-, but not those with normoalbuminuria. Treatment reduced urinary albumin excretion for Type 2 diabetic patients with and without microalbuminuria.
Comment in
- Viper venom for diabetic nephropathy.
Caramori ML. Caramori ML. Kidney Int. 2012 Apr;81(7):615-6. doi: 10.1038/ki.2011.460. Kidney Int. 2012. PMID: 22419043
Similar articles
- Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
Fegan PG, Davis WA, Kamber N, Sivakumar S, Beilby J, Davis TM. Fegan PG, et al. Diabet Med. 2011 Jul;28(7):849-55. doi: 10.1111/j.1464-5491.2011.03230.x. Diabet Med. 2011. PMID: 21231957 - Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
Taheri S, Asim M, Al Malki H, Fituri O, Suthanthiran M, August P; IDEAL-2 Study Team. Taheri S, et al. Trials. 2018 Apr 17;19(1):230. doi: 10.1186/s13063-018-2616-5. Trials. 2018. PMID: 29665833 Free PMC article. - Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ. Blacklock CL, et al. Diabet Med. 2011 Oct;28(10):1182-7. doi: 10.1111/j.1464-5491.2011.03341.x. Diabet Med. 2011. PMID: 21627686 - Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P, Rossing K, Parving HH. Jacobsen P, et al. Curr Opin Nephrol Hypertens. 2004 May;13(3):319-24. doi: 10.1097/00041552-200405000-00009. Curr Opin Nephrol Hypertens. 2004. PMID: 15073491 Review. - Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D. de Zeeuw D. Semin Nephrol. 2007 Mar;27(2):172-81. doi: 10.1016/j.semnephrol.2007.01.002. Semin Nephrol. 2007. PMID: 17418686 Review.
Cited by
- Management of Type 2 Diabetes Mellitus and Kidney Failure in People with HIV-Infection in Africa: Current Status and a Call to Action.
Wearne N, Davidson B, Blockman M, Jones J, Ross IL, Dave JA. Wearne N, et al. HIV AIDS (Auckl). 2023 Sep 6;15:519-535. doi: 10.2147/HIV.S396949. eCollection 2023. HIV AIDS (Auckl). 2023. PMID: 37700755 Free PMC article. Review. - The 2021-2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD.
de Sá JR, Rangel EB, Canani LH, Bauer AC, Escott GM, Zelmanovitz T, Bertoluci MC, Silveiro SP. de Sá JR, et al. Diabetol Metab Syndr. 2022 Jun 11;14(1):81. doi: 10.1186/s13098-022-00843-8. Diabetol Metab Syndr. 2022. PMID: 35690830 Free PMC article. - Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats.
Aggarwal D, Singh G. Aggarwal D, et al. Naunyn Schmiedebergs Arch Pharmacol. 2020 Apr;393(4):615-627. doi: 10.1007/s00210-019-01759-3. Epub 2019 Nov 26. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 31773183 - Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.
Voroneanu L, Siriopol D, Dumea R, Badarau S, Kanbay M, Afsar B, Gavrilovici C, Covic A. Voroneanu L, et al. Int Urol Nephrol. 2017 Dec;49(12):2195-2204. doi: 10.1007/s11255-017-1697-5. Epub 2017 Sep 25. Int Urol Nephrol. 2017. PMID: 28948420 Clinical Trial. - Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease.
Shen J, Huang YM, Song XN, Hong XZ, Wang M, Ling W, Zhang XX, Zhao HL. Shen J, et al. J Renin Angiotensin Aldosterone Syst. 2016 Jul 3;17(3):1470320316656481. doi: 10.1177/1470320316656481. Print 2016 Jul. J Renin Angiotensin Aldosterone Syst. 2016. PMID: 27377659 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical